Duarte MJ, Espinosa LRF, Sánchez RG, De Santiago LJ, Díaz MS, Lee Eng CVE

Idioma: Español
Referencias bibliográficas: 66
Paginas: 225-233
Archivo PDF: 93.57 Kb.

RESUMEN

El síndrome de respuesta inflamatoria sistémica (SRIS) es muy frecuente en pacientes críticamente enfermos, se encuentra en varias condiciones incluyendo trauma, cirugía y lesiones que generan hipoxia. Los signos clínicos y de laboratorio de inflamación sistémica, incluyen cambios en la temperatura corporal, taquicardia o leucocitosis, no son ni sensibles ni específicos para realizar el diagnóstico de sepsis. Este tema es de suma importancia porque la terapia y evolución difieren entre pacientes con y sin sepsis. Los cultivos microbiológicos pueden ser usados para distinguir a la sepsis de aquellas condiciones no infecciosas. Sin embargo, estos métodos carecen de sensibilidad y especificidad y frecuentemente son muy tardados. El uso indiscriminado de antibióticos en pacientes con SRIS pero sin sepsis, lleva al desarrollo de cepas resistentes y se incrementa la toxicidad y costos. La hiperglicemia es una causa importante de respuesta inflamatoria sistémica. Las angiopoyetinas son una clase nueva de factores de crecimiento angiogénicas que actúan selectivamente en las células endoteliales. La angiopoyetina 2 (ang 2) es sobrerregulada por diversos estímulos inflamatorios y promueve la inflamación y la fuga capilar, y puede participar en el desarrollo del proceso inflamatorio.

REFERENCIAS (EN ESTE ARTÍCULO)

1. American College of Chest Physicians, Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.

2. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000;26(Suppl 1):S64-S74.

3. Reinhart K, Meisner M, Hartog C. Diagnosis of sepsis: Novel and conventional parameters. Adv Sepsis 2001;1: 42-48.

4. Chopin N. Activated partial thromboplastin time waveform analysis: A new tool to detect infection? Crit Care Med 2006;34:1654-60.

5. Hennein HA, Ebba H, Rodríguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.

6. Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993;56:S92-S96.

7. Shapiro NI, Howell MD, Bates DW et al. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 2006;48:583-90.

8. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.

9. Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-755.

10. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.

11. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.

12. Rangel-Frausto M. The natural history of the systemic inflammatory response syndrome (SRIS): a prospective study. JAMA 1995;273:117-23.

13. Shapiro NI, Wolfe RE, Moore RB et al. Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. Crit Care Med 2003;31:670-75.

14. Shapiro NI, Howell MD, Talmor D et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524-528.

15. Jaimes F, Farbiarz J, Álvarez D et al. Comparison between logistic regression and neural networks to predict death in patients with suspected sepsis in the emergency department. Crit Care 2005;9:R150-R156.

16. Nguyen HB, Rivers EP, Knoblich BP et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-1642.

17. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003;29:530-8.

18. Carrillo ER. Modulación genética de la respuesta inflamatoria sistémica en sepsis. Rev Asoc Mex Med Crit y Ter Int 2001;15(3):92-5.

19. Talan DA. Dear SIRS: It’s time to return to sepsis as we have known it. Ann Emerg Med 2006;48:591-592.

20. Lemieux C, Maliba R, Favier J et al. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005;105:1523-1530.

21. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 2003;12:1-9.

22. Thurston G, Rudges JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.

23. Kim I, Moon SO, Park SK et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001;89:477-9.

24. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777.

25. Orfanos SE, Mavrommati I, Korovesi I et al. Pulmonary endothelium in acute lung injury: From basic science to the critically ill. Intensive Care Med 2004;30:1702-1714.

26. Orfanos SE. Angiopoietin-2 is increased in severe sepsis: Correlation with inflammatory mediators. Crit Care Med 2007;35:199-206.

27. Angstwurm MWA, Schottdorf J, Schopohl J et al. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit Care Med 1999;27:1807-13.

28. Forceville X, Vitoux D, Gauzit R et al. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med 1998;26:1536-44.

29. Berger MM. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med 2007;35[Suppl.]:S584-S590.

30. Berger MM. Antioxidant micronutrients in major trauma and burns: Evidence and practice. Nutr Clin Pract 2006;21:438-49.

31. Crimi E, Sica V, Williams-Ignarro S et al. The role of oxidative stress in adult critical care. Free Radic Biol Med 2006;40:398-406.

32. Heyland DK, Dhaliwal R, Day AG et al. Reducing deaths due to oxidative stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients. Proc Nutr Soc 2006;65:250-63.

33. Biesalski HK. Antioxidant therapy in critical care. Is the microcirculation the primary target? Crit Care Med 2007;35[Suppl.]:S577-S583).

34. Padeh S. Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 2007;33:585-623.

35. Zeerleder S. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003;31:1947-51.

36. Chello M. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006;34:660-7.

37. Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductasa blocks hypoxia-mediated down regulation of endothelial nitric oxide synthase. J Biol Chem 1997;272:31725-9.

38. Werdan K. Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome. The ESSICS study. Crit Care Med 2008;36:716-23.

39. Boden G, Ruiz J, Kim CJ at el. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 1996;270:E251-E258.

40. Peiro C, Lafuente N, Matesanz N et al. High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. Br J Pharmacol 2001;133:967-974.

41. Yano M, Hasegawa G, Ishii M et al. Short term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: Implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004;9:111-6.

42. Shanmugam N, Reddy MA, Guha M et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52:1256-64.

43. Noyman I, Marikovsky M, Sasson S et al. Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide 2002;7:187-93.

44. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: Clinical, cellular, and molecular aspects. Crit Care Med 2005;33:1624-33.

45. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-kappa B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005;175: 5423-29.

46. Ling PR, Smith RJ, Bistrian BR. Hyperglycemia enhances the cytokine production and oxidative response to a low but not high dose of endotoxin in rats. Crit Care Med 2005;33:1084-89.

47. Li H, Gu Y, Zhang Y et al. High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro. J Soc Gynecol Investig 2004;11:75-81.

48. Finney SJ, Zekveld C, Elia A et al. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-2047.

49. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr 2005;146:30-34.

50. Pei-Ra L. Acute effects of hyperglycemia and hyperinsulinemia on hepatic oxidative stress and the systemic inflammatory response in rats. Crit Care Med 2007;35:555-60.

51. Adnet F, Borron SW, Vicaut E et al. Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia, Chest 1997;112:466-71.

52. Dandona P, Nix D, Wilson MF. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-8.

53. Brunkhorst R. Procalcitonine for discrimination between activity of systemic autoinmune disease and systemic bacterial infection. Intensive Care Med 2000;26:S199-201.

54. Lynch J. Hospital-acquired pneumonia. Risk factors, microbiology and treatment. Chest 2001;119:S373-84.

55. Marshall J. Infection and the host septic response: implication for clinical trials of mediator antagonism. In: Vincent J-L, ed. Yearbook of intensive care and emergency medicine. Berlin: Springer-Verlag, 1994:3-13.

56. Brun-Buisson C, Doyon F, Carlet J et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995;274:968-74.

57. Young L. Gram-negative sepsis. In: Mandell G, Douglas R, Bennet J, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990:611-36.

58. Tang BMP. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-17.

59. Clec’h Ch. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006;34:102-7.

60. Parillo JE. Mechanisms of disease: Pathogenesis of septic shock. N Engl J Med 1993;328-33.

61. Vincent JL. Procalcitonin: The marker of sepsis? Crit Care Med 2000;28:1226-8.

62. Reinhart K, Meisner M, Hartog C. Diagnosis of sepsis: Novel and conventional parameters. Adv Sepsis 2001;2:42-8.

63. Vincent JL. Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 1997;25:372-4.

64. Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995;273:117-23.

65. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000;26:S74-S79.

66. Luzzani A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31: 1737-41.